FT-536 is under clinical development by Fate Therapeutics and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FT-536’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FT-536 is under development for the treatment of solid tumors, non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, triple-negative breast cancer (TNBC), urothelial cell carcinoma, squamous non-small cell lung cancer. The therapeutic candidate comprises CD38 gene knocked out induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells expressing a chimeric antigen receptor targeting MICA and MICB, a IL-15 receptor fusion (IL-15RF) and a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor. It is developed based on induced pluripotent stem cell (iPSC) product platform.
Fate Therapeutics overview
Fate Therapeutics is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. Its pipeline also includes a donor-derived cell product candidate for the treatment of hematological malignancies. Fate uses its proprietary human-induced pluripotent stem cell (iPSC) platform for product development. The company also has research collaborations with companies, academic centers, and medical centers for the advancement of products and technologies. Fate Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of FT-536’s drug-specific PTSR and LoA scores, buy the report here.